HIV virological failure and drug resistance in a cohort of Tanzanian HIV-infected adults

Hawkins, Claudia; Ulenga, Nzovu; Liu, Enju; Aboud, Said; Mugusi, Ferdinand; Chalamilla, Guerino; Sando, David; Aris, Eric; Carpenter, Deborah; Fawzi, Wafaie W.

doi:10.1093/jac/dkw051

Cited by 39 publications

(36 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…paediatrics). Hawkins et al 21 reported a prevalence of 14.9% and 75.7% for virological failure and HIV-DRM, respectively, while studying a population in north-west Tanzania. A study conducted by Ngarina et al 22 in the city of Dar es Salaam, Tanzania, among women for 24 months post-partum, documented a proportion of virological failure of 61% at 12 months on ART, with drug resistance demonstrated in 34%.…”

Section: Discussionmentioning

confidence: 99%

Strengthening HIV therapy and care in rural Tanzania affects rates of viral suppression

Ntamatungiro

Muri

Glass

et al. 2017

Journal of Antimicrobial Chemotherapy

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Strengthening HIV therapy and care in rural Tanzania affects rates of viral suppression

Ntamatungiro

Muri

Glass

et al. 2017

Journal of Antimicrobial Chemotherapy

View full text Add to dashboard Cite

show abstract

“…A higher viral load may lead to HIV treatment failure, which is becoming a threat of different African countries, like in Burkina Faso (6.4%) [10], Ghana (15.7%) [11], and Tanzania (14.9%) [12]. In Ethiopia, virological, immunological, and clinical failure is found in the range between 1.3% [13] to 11.5% [14], 2.1% [15] to 21% [16], and 3.1% [17] to 12.3% [18], respectively.…”

Section: Introductionmentioning

confidence: 99%

HIV/AIDS treatment failure and associated factors in Ethiopia: meta-analysis

et al. 2020

View full text Add to dashboard Cite

Background: The national burden of human immunodeficiency virus treatment failure and associated factors in the Ethiopian context is required to provide evidence towards a renewed ambitious future goal. Methods: We accessed Ethiopian Universities' online repository library, Google Scholar, PubMed, Web of Science, and Scopus to get the research articles. We run I-squared statistics to see heterogeneity. Publication bias was checked by using Egger's regression test. The pooled prevalence was estimated using the DerSimonian-Laird random-effects model. We employed the sensitivity analysis to see the presence of outlier result in the included studies. Results: The overall human immunodeficiency treatment failure was 15.9% (95% confidence interval: 11.6-20.1%). Using immunological, virological, and clinical definition, human immunodeficiency treatment failure was 10.2% (95% confidence interval: 6.9-13.6%), 5.6% (95% confidence interval: 2.9-8.3%), and 6.3% (95% confidence interval: 4.6-8.0%), respectively. The pooled effects of World Health Organization clinical stage III/IV (Adjusted Odd Ratio = 1.9; 95% CI: 1.3-2.6), presence of opportunistic infections (Adjusted Odd Ratio = 1.8; 95% CI: 1.2-2.4), and poor adherence to highly active antiretroviral therapy (Adjusted Odd Ratio = 8.1; 95% CI: 4.3-11.8) on HIV treatment failure were estimated. Conclusions: Human immunodeficiency virus treatment failure in Ethiopia found to be high. Being on advanced clinical stage, presence of opportunistic infections, and poor adherence to highly active antiretroviral therapy were the contributing factors of human immunodeficiency virus treatment failure. Human immunodeficiency virus intervention programs need to address the specified contributing factors of human immunodeficiency virus treatment failure. Behavioral intervention to prevent treatment interruption is required to sustain human immunodeficiency virus treatment adherence. Protocol registration: It has been registered in the PROSPERO database with a registration number of CRD42018100254.

show abstract

“…A higher viral load may leads to HIV treatment failure, which is becoming a threat of different African countries, like in Burkina Faso (6.4%) (12), Ghana (15.7%) (13), and Tanzania (14.9%) (14). In Ethiopia, virological, immunological, and clinical failure found to be in the range between 1.3% (15) to 11.5% (16), 2.1% (17) to 21% (18), and 3.1% (19) to 12.3% (20) respectively.…”

Section: Introductionmentioning

confidence: 99%

Still poor HAART adherence has great impact on HIV/AIDS treatment failure in Ethiopia

Endalamaw

Mekonen

Debebe

et al. 2018

Preprint

View full text Add to dashboard Cite

Background:The pooled burden of HIV treatment failure and its associated factors in Ethiopian context is required to provide evidence towards renewed ambitious future goal.Methods: Ethiopian Universities' (University of Gondar and Addis Ababa University) online repository library, Google scholar, PubMed, Web of Science, and Scopus were used to get the research articles. I-squared statistics was used to see heterogeneity. Publication bias was checked by Egger's regression test. The DerSimonian-Laird random effects model was employed to estimate the overall prevalence. Subgroup analysis based on geographical location of the study, study population by age, treatment failure type, and study design was conducted to see variation in outcomes. The sensitivity analysis was also employed to see whether the outlier result found in the included studies.

show abstract

HIV virological failure and drug resistance in a cohort of Tanzanian HIV-infected adults

Abstract: High levels of early ART failure and drug resistance were observed among Tanzanian HIV-1-infected adults enrolled in a well-monitored study. Initiating treatment early and ensuring optimal adherence are vital for the success and durability of first-line ART in these settings.

Cited by 39 publications

References 44 publications

Strengthening HIV therapy and care in rural Tanzania affects rates of viral suppression

Strengthening HIV therapy and care in rural Tanzania affects rates of viral suppression

HIV/AIDS treatment failure and associated factors in Ethiopia: meta-analysis

Still poor HAART adherence has great impact on HIV/AIDS treatment failure in Ethiopia

Contact Info

Product

Resources

About